Company news

Castle Biosciences, Inc. news in 2025

Castle Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 18, 2025

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

December 16, 2025

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

December 11, 2025

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

December 8, 2025

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

November 16, 2025

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

November 13, 2025

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

November 10, 2025

Castle Biosciences Reports Third Quarter 2025 Results

November 2, 2025

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

November 2, 2025

Castle Biosciences to Participate in Upcoming Investor Conferences

October 27, 2025

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

October 25, 2025

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

October 23, 2025

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

October 12, 2025

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

September 30, 2025

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

September 22, 2025

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

September 16, 2025

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

September 8, 2025

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

August 24, 2025

Castle Biosciences Reports Second Quarter 2025 Results

August 3, 2025

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

July 28, 2025

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

July 24, 2025

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

July 22, 2025

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

July 16, 2025

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

July 13, 2025

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

June 15, 2025

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

June 10, 2025

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

June 3, 2025

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 28, 2025

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 20, 2025

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 8, 2025

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 6, 2025

Castle Biosciences Reports First Quarter 2025 Results

May 4, 2025

Castle Biosciences to Acquire Previse

May 4, 2025

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

May 1, 2025

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

April 29, 2025

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

April 27, 2025

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

April 24, 2025

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

April 13, 2025

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

April 7, 2025

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

April 6, 2025

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

April 2, 2025

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

March 31, 2025

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

March 27, 2025

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

March 6, 2025

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

February 26, 2025

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

February 11, 2025

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

February 5, 2025

Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

January 16, 2025

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

January 11, 2025

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

January 5, 2025

Calls in 2025

Decks in 2025